Search
Cyclophosphamide Treatment Options
A collection of 2183 research studies where Cyclophosphamide is the interventional treatment. These studies are located in the United States . Cyclophosphamide is used for conditions such as Breast Cancer, Lymphoma and Leukemia.
769 - 780 of 2183
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Depressive disorder Clinical Study
Recruiting
A clinical study for people that suffer with Depressive disorder
Conditions:
Depressive disorder
Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer
Completed
The purpose of this study is to study the safety and clinical activity of nivolumab and ipilimumab in combination with either sequential administration of CY/GVAX pancreas vaccine followed by CRS-207 (Arm A) or with administration of CRS-207 alone (Arm B) in patients with pancreatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2024
Locations: Johns Hopkins SKCCC, Baltimore, Maryland
Conditions: Pancreatic Cancer
Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
Completed
The purpose of this study is to determine whether nifurtimox in combination with cyclophosphamide and topotecan are effective in the treatment of relapsed or refractory neuroblastoma and medulloblastoma.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
08/02/2024
Locations: Rady Children's Hospital, San Diego, California +14 locations
Conditions: Neuroblastoma, Medulloblastoma
FT576 in Subjects With Multiple Myeloma
Active Not Recruiting
This is a Phase I dose-finding study of FT576 as monotherapy and in combination with the monoclonal antibody daratumumab in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama +13 locations
Conditions: Multiple Myeloma, Myeloma
FT819 in Subjects With B-cell Malignancies
Active Not Recruiting
This is a Phase I dose-finding study of FT819 as monotherapy and in combination with IL-2 in subjects with relapsed/refractory B-cell Lymphoma, Chronic Lymphocytic Leukemia and Precursor B-cell Acute Lymphoblastic Leukemia. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama +16 locations
Conditions: Lymphoma, B-Cell, Chronic Lymphocytic Leukemia, Precursor B-Cell Acute Lymphoblastic Leukemia
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
Terminated
This study will evaluate the efficacy, safety, and pharmacokinetics of adjuvant atezolizumab in combination with paclitaxel, followed by atezolizumab, dose-dense doxorubicin or epirubicin (investigator's choice), and cyclophosphamide, compared with paclitaxel followed by dose-dense doxorubicin or epirubicin (investigator's choice) and cyclophosphamide alone in patients with Stage II-III TNBC (Triple Negative Breast Cancer)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2024
Locations: John Muir Health Clinical Research Center, Concord, California +363 locations
Conditions: Triple Negative Breast Cancer
FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)
Recruiting
This is a phase 1 study of FT522 administered with rituximab in participants with relapsed/refractory B-cell lymphoma (R/R BCL). The primary objectives of the study are to evaluate the safety and tolerability of FT522 in combination with rituximab, and to determine the recommended phase 2 dose (RP2D) of FT522 in combination with rituximab; each objective will be assessed with or without conditioning chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2024
Locations: Karmanos Cancer Center, Detroit, Michigan +5 locations
Conditions: Relapsed/Refractory B-Cell Lymphoma
QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed
Terminated
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with SCC who have progressed on or after previous platinum-based chemotherapy and anti-PD-1/PD-L1 therapy. Phase 2 will be based on Simon's two-stage optimal design.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2024
Locations: Chan Soon-Shiong Institute for Medicine, El Segundo, California
Conditions: Squamous Cell Carcinoma
Pancreatic Tumor Cell Vaccine (GVAX), Cyclophosphamide, SBRT, and FOLFIRINOX in Patients With Resected Adenocarcinoma of the Pancreas
Completed
The purpose of this study is to estimate safety of GVAX Pancreas Vaccine (GVAX) with immune modulating doses of cyclophosphamide (Cy) followed by SBRT and FOLFIRINOX chemotherapy in pancreatic cancer patients after surgery.
Gender:
ALL
Ages:
Between 18 years and 76 years
Trial Updated:
07/22/2024
Locations: The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Pancreatic Cancer
A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)
Terminated
This is a Phase 1/2, open-label, single arm, multicohort study to evaluate the safety and efficacy of JCAR017 in pediatric subjects aged ≤ 25 years with CD19+ r/r B-ALL and B-NHL.
Phase 1 will identify a recommended Phase 2 dose (RP2D). Phase 2 will evaluate the efficacy of JCAR017 RP2D in the following three disease cohorts: Cohort 1 (r/r B-ALL), Cohort 2 (MRD+ B-ALL) and Cohort 3 (r/r B-NHL, \[DLBCL, BL, or PMBCL\]). A Simon's Optimal two-stage study design will be applied to Cohort 1 and 2 i... Read More
Gender:
ALL
Ages:
25 years and below
Trial Updated:
07/22/2024
Locations: Local Institution - 163, Duarte, California +18 locations
Conditions: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin
Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.
Terminated
A phase 1/2 study to assess the safety and efficacy of MB-102 in patients with relapsed or refractory BPDCN
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/19/2024
Locations: City of Hope Medical Center, Duarte, California +3 locations
Conditions: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Ph I/II Study of CAR19 Regulatory T Cells (CAR19-tTreg) for R/R CD19+ B-ALL
Withdrawn
This is a single-center, single-arm, interventional phase I/II trial to evaluate the safety profile and potential efficacy of allogeneic CAR19 regulatory T cells (CAR19-tTreg) in adults with relapsed/refractory (R/R) CD19+ B Acute Lymphocytic Leukemia (B-ALL).
The study consists of two components. The dose finding component is a modified version of a Phase I trial and the extended component is a modified Phase II trial.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2024
Locations: Masonic Cancer Center - University of Minnesota, Minneapolis, Minnesota
Conditions: Lymphoma Leukemia
CAR- PRISM (PRecision Intervention Smoldering Myeloma)
Recruiting
The goal of this research study is to test if ciltacabtagene autoleucel (cilta-cel) is safe and effective in treating participants with high-risk, smoldering myeloma.
The names of the treatment interventions used in this study are:
* Cilta-cel (or chimeric antigen receptor T cells)
* Cyclophosphamide (a lymphodepleting chemotherapy)
* Fludarabine (a lymphodepleting chemotherapy)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Multiple Myeloma, Smoldering Multiple Myeloma
769 - 780 of 2183